- The key vendors in the Global Overactive Bladder Therapeutics Market 2014-2018 are Actavis plc., Allergan Inc., Astellas Pharma Inc. and Pfizer Inc.
London, 28 October 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Overactive Bladder Therapeutics Market 2014-2018. One major trend emerging in this market is the increase in awareness about overactive bladder syndrome. It results in an increase in the consumption of medications, thereby, contributing to the growth of the market. The Global Overactive Bladder Therapeutics market is expected to grow at a CAGR of 1.14 percent during the period 2013-2018.
“The launch of new drugs can partially offset the loss incurred due to the expiry of patents of major drugs, which, in the past, has led to a decrease in the revenues of leading vendors in the Global Overactive Bladder Therapeutics market,” says Faisal Ghaus, Vice President of TechNavio Research.
“There are certain issues with the safety and efficacy profiles of these drugs, which imply that a significant opportunity exists in the market for new entrants to capitalize on.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
